OKUR (OnKure Therapeutics) Pre-Tax Income : $-62.56 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. OnKure Therapeutics's pretax income for the three months ended in Dec. 2024 was $-35.19 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-62.56 Mil. OnKure Therapeutics's pretax margin was %.

OnKure Therapeutics Pre-Tax Income Historical Data

The historical data trend for OnKure Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics Pre-Tax Income Chart

OnKure Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Pre-Tax Income

-29.51

-35.31

-52.67

OnKure Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial				18.52	-9.54	-14.14	-3.69	-35.19

Competitive Comparison of OnKure Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, OnKure Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OnKure Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where OnKure Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

OnKure Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

OnKure Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-54.386	+	1.713	+	-0.3	+	2.013	+	-1.713
	=	-52.67

OnKure Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-33.795	+	1.257	+	0	+	0	+	-2.656
	=	-35.19

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.56 Mil.

OnKure Therapeutics (NAS:OKUR) Pre-Tax Income Explanation

OnKure Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-35.194	/	0
	=	%

OnKure Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of OnKure Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

OnKure Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301

Website

https://www.onkuretherapeutics.com

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.